Clinical Trials Arena November 11, 2024
As more becomes known about the types of T cells used for CAR-T therapies, also known as alpha beta (ɑβ) CD3+ T cells, so do the strengths of less conventional subsets such as gamma delta (γδ) T cells. We explore the immense potential of gamma delta T cells, as well as the challenges in sourcing and scaling up sufficient volumes to treat enough patients.
Gamma delta (γδ) T cells hold significant potential for unmet medical needs. Yet they are more challenging to source than other T cells, representing as little as 1% to 5% of the total CD3+ T-cell population in peripheral blood.1 Crucially, the mechanism of action of gamma delta T cells means they can operate in an HLA-independent...
Today's Sponsors
Today's Sponsor